XP Chemistries AB Stocks

SEK 0.19Last Updated 11.03.2026

Issuer Rating

2/7

Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

SEK 4.12M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 0.19
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

XP Chemistries AB, a biotechnology company, develops and produces forest-based capsaicin and analogues. It offers animal feed ingredients, cosmetic ingredients, pure capsaicinoids, and self-defense liquid and ingredients. The company was incorporated in 2018 and is based in Sundsvall, Sweden.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks